PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Follow-Up Study for Exubera
- First Posted Date
- 2008-08-14
- Last Posted Date
- 2012-10-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 7439
- Registration Number
- NCT00734591
- Locations
- 🇬🇧
Pfizer Investigational Site, Westbury, United Kingdom
Tanezumab in Osteoarthritis of the Knee
Phase 3
Completed
- Conditions
- ArthritisOsteoarthritis
- Interventions
- Biological: PlaceboBiological: tanezumab
- First Posted Date
- 2008-08-13
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 697
- Registration Number
- NCT00733902
- Locations
- 🇺🇸
Stamford Therapeutics Consortium, Stamford, Connecticut, United States
🇺🇸Delray Research Associates, Delray Beach, Florida, United States
🇺🇸University Clinical Research Incorporated, Pembroke Pines, Florida, United States
Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease
Phase 1
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- Biological: PF-04360365 1 mg/kgBiological: PF-04360365 3 mg/kgBiological: PF-04360365 5 mg/kgBiological: PF-04360365 10 mg/kg
- First Posted Date
- 2008-08-13
- Last Posted Date
- 2009-07-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT00733642
- Locations
- 🇺🇸
Pfizer Investigational Site, Oakhurst, New Jersey, United States
A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies
- First Posted Date
- 2008-08-12
- Last Posted Date
- 2011-03-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT00732992
- Locations
- 🇯🇵
Pfizer Investigational Site, Osakasayama-shi, Osaka, Japan
An Investigation Of The Effects Of Food On The Absorption Of A Varenicline Controlled Release Formulation
Phase 1
Completed
- Conditions
- PharmacokineticsBioavailabilitySmoking Cessation
- Interventions
- First Posted Date
- 2008-08-11
- Last Posted Date
- 2010-01-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00731562
- Locations
- 🇺🇸
Pfizer Investigational Site, Fargo, North Dakota, United States
Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- Advanced CancerAdvanced Solid Tumors
- Interventions
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 45
- Registration Number
- NCT00729833
- Locations
- 🇺🇸
Pfizer Investigational Site, San Antonio, Texas, United States
A Phase I, Healthy Volunteer Positron Emission Tomography Study
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Other: Positron Emission tomographyDrug: PET Scan with PF-03654746
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2019-03-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 10
- Registration Number
- NCT00730990
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2010-02-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8
- Registration Number
- NCT00730145
- Locations
- 🇺🇸
Pfizer Investigational Site, Orlando, Florida, United States
Efficacy And Safety Of PF-00885706 For The Relief Of Symptoms In Subjects With Gastro-esophageal Reflux Disease (GERD)
Phase 2
Terminated
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2011-07-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 81
- Registration Number
- NCT00730665
- Locations
- 🇪🇸
Pfizer Investigational Site, Sevilla, Spain
Assessing Prevalence Of Beta Lactamase Production From Clinical Isolates Of Hospitalized Patients And Comparison Of Antibiotic Susceptibility Patterns
Completed
- Conditions
- Infection
- First Posted Date
- 2008-08-06
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2039
- Registration Number
- NCT00728624
- Locations
- 🇮🇳
Pfizer Investigational Site, New Delhi, India
© Copyright 2025. All Rights Reserved by MedPath